Bionano Announces the Final Speaker Lineup for 2024 Symposium with 33 OGM Presentations and Live Panel Discussions Across a Wide Range of Research Applications
19 Janvier 2024 - 2:00PM
Bionano Genomics, Inc (Nasdaq: BNGO) today announced its 2024
Symposium lineup of 33 oral presentations delivered by 26 different
customers worldwide featuring the utility of optical genome mapping
(OGM) across a wide range of research applications in cancer, cell
and gene therapy, and genetic disease. 2024 Symposium will take
place virtually from January 22 to 25, 2024. During these four
days, customers will showcase their latest research findings using
OGM. Each day will feature user presentations, a live panel with
Q&A, and scientific posters within the virtual exhibition hall.
On day 2, Bionano will unveil a new product expected to advance
cytogenetics and structural variant analysis.
“We believe 2024 Symposium is an opportunity for the OGM
community to come together and share the progress they are making
in translational research using OGM alongside other genome analysis
tools,” said Erik Holmlin, PhD, president and chief executive
officer of Bionano Genomics. “Symposium provides a chance for
anyone interested or currently working with OGM to form connections
within the community and see the potential impact of looking at the
genome in a different way. We believe this year’s event will be our
best to date, with an expanded focus on the use of OGM in cell and
gene therapy, as well as some very exciting product announcements
that will drive further research advancements.”
“Our 2023 Symposium was a fantastic event where OGM users shared
their data covering genetic disorder and cancer research. Since
then, we have made significant improvements in our end-to-end
workflow which we believe has enabled our customers to advance
their clinical and translational research. The presentations at
this year’s event have been elevated to a new level, with dedicated
sessions on advancements in heme malignancy research and solid
tumor analysis, updates from global consortia driving OGM adoption,
and new OGM data from researchers focused on solving constitutional
diseases and rare disease,” said Alka Chaubey, PhD, FACMG,
chief medical officer at Bionano. “Symposium attendees have a
unique opportunity to learn from their peers, network, and view
scientific posters and new products that we will showcase each
day.”
Each session of Symposium will start at 7:00 am
PST and will last approximately 3 hours. After the scientific
presentations, the speakers will join for a live panel discussion
and Q&A moderated by Dr. Chaubey. In addition, each day
will feature a scientific poster exhibit. Below is the list of
customer presentations for each day and the application area.
January 22: New Standards in Hematological Malignancies
Speaker |
Institution |
Title |
Dr. Tiffany Clouston |
Saint John Regional Hospital |
Optical Genome Mapping: Pivoting Towards a New Technology |
Dr. Ying Zou |
Johns Hopkins University School of Medicine |
Comprehensive Genome-wide Genetic Profile in Plasma Cell Neoplasm
by OGM |
Dr. Guilin Tang |
University of Texas MD Anderson Cancer Center |
Optical Genome Mapping (OGM) in T-lymphoblastic Leukemia
(T-ALL) |
Dr. Yanming Zhang |
Memorial Sloan Kettering Cancer Center |
Clinical Research Applications of Optical Genome Mapping (OGM) in
Cancer Cytogenetics |
Dr. Agnes Daudignon |
Lille Hospital |
FrOGG: French Speaking OGM Group from GFCH |
Dr. Adam Smith |
University of Toronto |
The "Framework" for the Clinical Research Implementation of Optical
Genome Mapping in Hematologic Malignancies |
Daniel Saul |
Bionano |
Advancements in Informatics and Software for OGM Data Analysis |
January 23: New Frontiers in Oncology
Speaker |
Institution |
Title |
Dr. Marc-Henri Stern |
Institut Curie |
Features of Homologous Recombination Deficiency (HRD) in Solid
Tumors Using Optical Genome Mapping |
Dr. Isabelle Raymound-Bouchard |
Hôpital Maisonneuve-Rosemont |
Developing Optical Genome Mapping for CD 138+ Plasma Cells |
Dr. Scott Ryall |
Brigham and Women’s Hospital |
Illuminating a New Path Forward for Cancer Research |
Dr. Ravindra Kolhe |
Augusta University |
Novel Biomarkers Unveiled by Utilization of OGM in Cancer
Investigations |
Dr. Trilochan Sahoo |
Bionano Laboratories |
A Prospective Study of Optical Genome Mapping in Hematologic
Malignancies |
Dr. Deb Tweddle |
Newcastle University |
Novel Structural Variants Detected by Optical Genome Mapping in
Neuroblastoma |
Dr. Miriam Bornhorst |
Lurie Children’s Hospital of Chicago |
Application of Optical Genome Mapping for Pediatric Brain Tumors:
Solving Challenging Cases |
Dr. Adrian Dubuc |
Roswell Park Comprehensive Cancer Center |
Raising the Bar: Comprehensive Cytogenetic Profiling for Improved
Lymphoma Analysis |
Darisha Jiandani |
Bionano |
The Next Major OGM Advancement: Unlocking Flexible Structural
Variant Analysis at Scale |
January 24: Advances in Constitutional Applications
Speaker |
Institution |
Title |
Dr. Roger Stevenson |
Equinamitas |
Optical Genome Mapping for Prenatal Genetic Testing – Multisite
Evaluation and Validation |
Dr. Roger Stevenson |
Equinamitas |
Detection of Constitutional Structural Variants by Optical Genome
Mapping – A Multisite Study of Postnatal Samples |
Dr. Nikhil Sahajpal |
Greenwood Genetic Center |
Optical Genome Mapping in Rare Disorders |
Dr. Noemi Buisset |
Medicover Genetics |
Insights from Optical Genome Mapping: Uncovering Discrepancies in
Chorionic Villi STC and LTC |
Dr. Laila El Khattabi |
AP-HP Sorbonne |
The CHROMAPS study: First Results from Optical Genome Mapping |
Dr. Maria Clara Bonaglia |
Scientific Institute E. Medea |
Optical Genome Mapping (OGM): Refining Genotype Phenotype
Correlation in Different Types of Structural Variants |
Dr. Yassmine Akkari |
Nationwide Children’s Hospital |
Optical Genome Mapping (OGM) Identifies Multiple Structural
Variants in a Case with Atypical Phelan-McDermid
Syndrome |
Dr. Ulrich Brockel |
Medical College of Wisconsin |
Optical Genome Mapping for Constitutional Chromosome Analysis |
Dr. Madhuri Hedge |
Revvity |
Molecular Analysis of Facioscapulohumeral Muscular Dystrophy Using
Optical Genome Mapping |
Tanushi Sahai |
Bionano |
The Sample Preparation Landscape for Optical Genome Mapping |
January 25: OGM in Cell and Gene Therapy
Speaker |
Institution |
Title |
Dr. Alex Hastie |
Bionano |
Detection of CRISPR Related Structural Variants in Genome Edited
Hematopoietic Stem Cells in X-SCID Disease |
Dr. Sam Dougaparsad |
Bionano |
Optical Genome Mapping: Revolution in Quality Control for Cell
Genomic Integrity |
Dr. John Yu |
Chang Gung Memorial Hospital |
Whole Genomic Analysis Reveals Atypical Non-Homologous Off-target
Large Structural Variants Induced by CRISPR-Cas9-mediated Genome
Editing |
Dr. Samantha Maragh |
National Institute of Standards and Technology |
Initial Outcomes of Variant Detection and Quantitation from the
First NIST Genome Editing Consortium Interlab Study |
Dr. Andy Pang |
Bionano |
Genome Integrity QC Using Optical Genome Mapping – A Technical
Guide |
Owen Pearce |
eGenesis |
Engineering Porcine Genomes for Xenotransplantation: Detecting
Structural Variants in Engineered Genomes Using Optical Genome
Mapping |
Dr. Saumyaa Saymyaa |
AstraZeneca |
Applications of OGM in Cell and Gene Therapy |
Symposium registration is open to all and there is no charge for
attending this event. Register today
at https://bionanosymposium2024.vfairs.com/.
About Bionano
Bionano is a provider of genome analysis solutions that can
enable researchers and clinicians to reveal answers to challenging
questions in biology and medicine. The Company’s mission is to
transform the way the world sees the genome through OGM solutions,
diagnostic services and software. The Company offers OGM solutions
for applications across basic, translational and clinical research.
Through its Lineagen, Inc. d/b/a Bionano Laboratories business, the
Company also provides diagnostic testing for patients with clinical
presentations consistent with autism spectrum disorder and other
neurodevelopmental disabilities. The Company also offers an
industry-leading, platform-agnostic software solution, which
integrates next-generation sequencing and microarray data designed
to provide analysis, visualization, interpretation and reporting of
copy number variants, single-nucleotide variants and absence of
heterozygosity across the genome in one consolidated view. The
Company additionally offers nucleic acid extraction and
purification solutions using proprietary isotachophoresis
technology. For more information, visit www.bionano.com,
www.bionanolaboratories.com or www.purigenbio.com.
Unless specifically noted otherwise, Bionano’s OGM products
are for research use only and not for use in diagnostic
procedures.
Forward-Looking Statements of Bionano
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Words such as “believe,” “potential,” “will”
and similar expressions (as well as other words or expressions
referencing future events, conditions or circumstances and the
negatives thereof) convey uncertainty of future events or outcomes
and are intended to identify these forward-looking statements.
Forward-looking statements include statements regarding our
intentions, beliefs, projections, outlook, analyses or current
expectations concerning, among other things, the anticipated
benefits of the 2024 Symposium, the potential for OGM to be adopted
for applications discussed at the 2024 Symposium, and the ability
and utility of OGM to be adopted for applications in genetic
disease and cancer research and for cell and gene therapy and other
applications discussed at the 2024 Symposium. Each of these
forward-looking statements involves risks and uncertainties. Actual
results or developments may differ materially from those projected
or implied in these forward-looking statements. Factors that may
cause such a difference include the risks and uncertainties
associated with: the impact of geopolitical and macroeconomic
developments, such as recent and future bank failures, the
ongoing Ukraine-Russia conflict, related sanctions, the
Israel-Hamas war, and any global pandemics, on our business and the
global economy; challenges inherent in developing, manufacturing
and commercializing products; our ability to further deploy new
products and applications and expand the markets for our technology
platforms; changes in the competitive landscape and the
introduction of competitive technologies or improvements to
existing technologies; failure of future study results to support
those reported and discussed at the 2024 Symposium; future study
results that contradict the results discussed and reported at the
2024 Symposium; failure of OGM to be adopted for applications in
genetic disease and cancer research and for cell and gene therapy
and other applications discussed at the 2024 Symposium; changes in
our strategic and commercial plans; our ability to obtain
sufficient financing to fund our strategic plans and
commercialization efforts; the ability of medical and research
institutions to obtain funding to support adoption or continued use
of our technologies; and the risks and uncertainties associated
with our business and financial condition in general; our
expectations and beliefs regarding future growth of the business
and the markets in which we operate; changes in our strategic and
commercial plans; our ability to obtain sufficient financing to
fund our strategic plans and commercialization efforts and our
ability to continue as a “going concern”; and including the risks
and uncertainties described in our filings with the Securities
and Exchange Commission, including, without limitation, our Annual
Report on Form 10-K for the year ended December 31,
2022 and in other filings subsequently made by us with
the Securities and Exchange Commission. All forward-looking
statements contained in this press release speak only as of the
date on which they were made and are based on management’s
assumptions and estimates as of such date. We are under no duty to
update any of these forward-looking statements after the date they
are made to conform these statements to actual results or revised
expectations, except as required by law. You should, therefore, not
rely on these forward-looking statements as representing our views
as of any date subsequent to the date the statements are made.
Moreover, except as required by law, neither we nor any other
person assumes responsibility for the accuracy and completeness of
the forward-looking statements contained in this press release.
CONTACTSCompany Contact:Erik
Holmlin, CEOBionano Genomics, Inc.+1 (858)
888-7610eholmlin@bionano.com
Investor Relations:David HolmesGilmartin
Group+1 (858) 888-7625IR@bionano.com
Bionano Genomics (NASDAQ:BNGO)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Bionano Genomics (NASDAQ:BNGO)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024